Neuropeptides as autocrine growth factors in cancer cells.
about
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease statesHuman gastrin-releasing peptide receptor gene regulation requires transcription factor binding at two distinct CRE sitesNeuroendocrine differentiation in prostate cancerIs the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?Insights into bombesin receptors and ligands: Highlighting recent advancesPeptidomics: a logical sequel to proteomics.Bombesin receptor subtype 3 as a potential target for obesity and diabetes.HIF1alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiation.Array-based DNA methylation profiling for breast cancer subtype discrimination.Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon.Bombesin receptor-mediated imaging and cytotoxicity: review and current statusVIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies.Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis.Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells.Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancerTargeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies.Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent mannerContinuing pursuit for ideal systemic anticancer radiotherapeutics.Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin.Expression of the SST receptor 2 in uveal melanoma is not a prognostic marker.Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples.Heat shock protein 27 mediates repression of androgen receptor function by protein kinase D1 in prostate cancer cells.Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells.Early over-expression of GRP receptors in prostatic carcinogenesis.Intrinsic denervation of the colon is associated with a decrease of some colonic preneoplastic markers in rats treated with a chemical carcinogen.A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma.Acinar cell carcinoma of the pancreas in a young patient with cells immunoreactive for somatostatin.
P2860
Q24643524-7208E0D9-EF45-4947-BC1E-E28435816E56Q24649884-14501CD9-ED5F-41ED-AD15-D8946ADE89C1Q24657547-506DC092-BECE-4872-A8DD-0D48E0019AB0Q26748741-ECF1AD16-3514-4F7A-93C5-A996D5549621Q28081153-8BF8C8C3-3243-4FBB-8E21-D223F39857D0Q33221666-527B8B97-A8C6-4D85-9E30-5A1232D63175Q33637115-3826B85A-C0EC-4C5F-9E66-FA132888D8EBQ33642200-16C9396E-B9D3-403F-BC08-7E260A848A57Q33689442-07D077C3-F069-4206-BA5B-AE81E9F39706Q33769389-0C9295D1-5124-476E-9FC7-D9E05C3DA0C7Q34365380-A0E6D078-990B-445F-BFAD-3EC58B122C36Q34684387-5057DE07-EDF0-4C64-A490-02868B22326AQ34788079-8890029F-C649-4A91-8BC2-7DA59FA338D5Q34979549-7E93A148-6316-420A-83CA-A45866BC410BQ35154092-9D733BF6-1DEF-49AA-8F75-7D8ADAB6F3BEQ35996716-F8104C52-598F-4B2B-BFE5-1B1766F6EA4DQ36166344-709E6515-504C-4A00-A42B-2A7D76B9C268Q36834005-2D821122-2FCD-4BBD-BCA4-505B60855D8CQ37230848-681DCE91-1F50-4777-B650-CE478918D572Q37342513-D6E84248-F555-46BA-8409-AA99FD19713CQ37395737-8033B676-D085-4938-A0BB-58BA21E2A71DQ37398035-7A851EBD-82FD-43C4-B3E4-D9956F83FB9CQ37662776-1D1FD45F-A20A-470C-A075-856D87AABD88Q37946750-6AC748D0-29BD-41AF-AD6A-4C871BBDF341Q38776596-853DAD81-6916-452B-A9B7-FFFD7DFA8CD1Q39378866-6EC105BC-7317-4CD9-9A81-DC3162D66FC4Q39478560-38F7BBC1-49C2-4962-B484-F828424BE720Q39953555-4CEB1948-8948-41A1-8324-A12380217F7DQ40445054-47849EB2-2B7E-4A2A-B0F3-FD5D6F60B5B4Q43273887-A5847CFF-8610-47D2-A2D0-4B46152DC031Q44797073-41E3BED7-5156-4641-8966-15F2E53E33CEQ46266299-D0203711-01A9-458B-BBF6-ADAAE53A8006Q46736017-0A32F168-3A14-4723-AB3C-1E178C7DB356Q50149052-E285FA0D-8C7A-4129-A227-74083E9CE32CQ51547854-C8A24052-EF38-4A9A-AA1D-2B27B4C4D84FQ53555112-174B4402-FCF5-4455-B78A-5F55D4055CDF
P2860
Neuropeptides as autocrine growth factors in cancer cells.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Neuropeptides as autocrine growth factors in cancer cells.
@ast
Neuropeptides as autocrine growth factors in cancer cells.
@en
type
label
Neuropeptides as autocrine growth factors in cancer cells.
@ast
Neuropeptides as autocrine growth factors in cancer cells.
@en
prefLabel
Neuropeptides as autocrine growth factors in cancer cells.
@ast
Neuropeptides as autocrine growth factors in cancer cells.
@en
P2093
P356
P1476
Neuropeptides as autocrine growth factors in cancer cells.
@en
P2093
Daniel Chan
Jan Fahrenkrug
Robert T Jensen
Terry W Moody
P304
P356
10.2174/1381612033391621
P577
2003-01-01T00:00:00Z